PPV of serum and urine early normalization (cycles 1 and 3) for MRD response (by flow cytometry) postconsolidation
. | Method . | Method result . | Achieving MRD negativity . | ||
---|---|---|---|---|---|
Yes . | No . | PPV, % . | |||
Cycle 1 (n = 43) | uIFE negative | Yes | 17 | 4 | 81 |
No | 12 | 10 | |||
sFLC ratio normal | Yes | 9 | 0 | 100 | |
No | 20 | 14 | |||
Cycle 3 (n = 66) | uIFE negative | Yes | 40 | 11 | 78 |
No | 5 | 10 | |||
sFLC ratio normal | Yes | 22 | 0 | 100 | |
No | 23 | 21 |
. | Method . | Method result . | Achieving MRD negativity . | ||
---|---|---|---|---|---|
Yes . | No . | PPV, % . | |||
Cycle 1 (n = 43) | uIFE negative | Yes | 17 | 4 | 81 |
No | 12 | 10 | |||
sFLC ratio normal | Yes | 9 | 0 | 100 | |
No | 20 | 14 | |||
Cycle 3 (n = 66) | uIFE negative | Yes | 40 | 11 | 78 |
No | 5 | 10 | |||
sFLC ratio normal | Yes | 22 | 0 | 100 | |
No | 23 | 21 |